Kowa Study

A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week, Phase 2 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Patients with Fuchs Endothelial Corneal Dystrophy

Purpose of the Study

This is a multi-center, double-masked, randomized, parallel-group, placebo-controlled, 2-period study of patients with FECD after descemetorhexis.

Basic Eligibility Criteria

• Age 18 or older
• Diagnosed with Fuchs endothelial corneal dystrophy

How to Contact Us

Principal Investigator: Dr. Ahmed Omar
Study contact: Leslie Richards I 216-844-0794